**Supplementary Table 2. Haplotype frequency**

| Haplotype | Frequency (%) | Patients who received irinotecan-containing chemotherapy (n = 98) |
|-----------|--------------|---------------------------------------------------------------|
| UGT1A9*22 118(T)10/(T)9 | | |
| UGT1A7 | UGT1A1*60 3279T/G | UGT1A1*28 -53(TA)6>7 | UGT1A1*6 211G/A | Total (n = 382) | |
| I | TCGT(*1) | T | 6 | G | 48.66 | 48.98 |
| II | GAAC(*3) | T | 6 | A | 17.35 | 16.84 |
| III | GAAT(*2) | G | 6 | G | 15.33 | 16.84 |
| IV | TCGT(*1) | G | 7 | G | 8.66 | 6.12 |
| V | GAAT(*2) | G | 7 | G | 1.98 | 2.55 |
| VI | GAAC(*3) | G | 7 | G | 1.77 | 4.08 |
| VII | GAAC(*3) | T | 6 | A | 1.76 | 1.53 |
| VIII | GAAC(*3) | T | 6 | G | 1.67 | 0.51 |
| IX | TCGT(*1) | G | 6 | G | 0.93 | 0.51 |
| X | TCGT(*1) | T | 6 | A | 0.52 | 0.00 |
| XI | GAAT(*2) | T | 6 | A | 0.39 | 0.00 |
| XII | GAAC(*3) | G | 7 | G | 0.29 | 1.02 |
| XIII | GAAC(*3) | G | 6 | G | 0.26 | 0.00 |
| XIV | GAAT(*2) | T | 6 | G | 0.26 | 0.51 |
| XV | GAAT(*2) | G | 6 | G | 0.17 | 0.51 |